Therapeutic Efficacy of an Angiotensin II Receptor Antagonist in Patients with Nonalcoholic Steathepatitis

Therapeutic Efficacy of an Angiotensin II Receptor Antagonist in Patients with Nonalcoholic Steathepatitis - GLSG, 2004, ARB

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000202

Enrollment

Registered

2005-09-13

Start date

2004-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic steatohepatitis

Interventions

Angiotensin II receptor Antagonist 1 or 2 tablets per day for at least 48 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Nonalcoholic steatohepatitis (NASH) Resistanace to nutritional treatment or exercise complication with hypertension

Exclusion criteria

Exclusion criteria: Allergy to Angiotensin II receptor Antagonist(ARB) complication with liver diseases due to other causes secondary NASH medication history of ARB or ACE inhibitors

Design outcomes

Primary

Measure	Time frame
transaminase	—

Secondary

Measure	Time frame
insulin resistance liver histology	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026